These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Immunomodulatory effects of intravenous and subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: An observational study. Svačina MKR; Meißner A; Schweitzer F; Ladwig A; Pitarokoili K; Kofler DM; Sprenger-Svačina A; Schneider C; Kohle F; Klein I; Wüstenberg H; Lehmann HC Eur J Neurol; 2024 Jan; 31(1):e16079. PubMed ID: 37789648 [TBL] [Abstract][Full Text] [Related]
8. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. Markvardsen LH; Christiansen I; Jakobsen J Transfusion; 2016 Oct; 56(10):2443-2448. PubMed ID: 27401495 [TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG? Allen JA; Gelinas DF; Freimer M; Runken MC; Wolfe GI J Neurol Sci; 2020 Jan; 408():116497. PubMed ID: 31765922 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Tolerability of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Neurologic Diseases. Chen Y; Wang C; Xu F; Ming F; Zhang H Clin Ther; 2019 Oct; 41(10):2112-2136. PubMed ID: 31445679 [TBL] [Abstract][Full Text] [Related]
11. Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis. Lazzaro C; Lopiano L; Cocito D Neurol Sci; 2014 Jul; 35(7):1023-34. PubMed ID: 24469345 [TBL] [Abstract][Full Text] [Related]
12. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years. Gentile L; Mazzeo A; Russo M; Arimatea I; Vita G; Toscano A Sci Rep; 2020 May; 10(1):7910. PubMed ID: 32404895 [TBL] [Abstract][Full Text] [Related]
18. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. van Schaik IN; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Praus M; Mielke O; Durn BL; Cornblath DR; Merkies ISJ; Lancet Neurol; 2018 Jan; 17(1):35-46. PubMed ID: 29122523 [TBL] [Abstract][Full Text] [Related]
19. Expanding the Role of the Pharmacist: Immunoglobulin Therapy and Disease Management in Neuromuscular Disorders. Tichy EM; Prosser B; Doyle D J Pharm Pract; 2022 Feb; 35(1):106-119. PubMed ID: 32677504 [TBL] [Abstract][Full Text] [Related]
20. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Lee DH; Linker RA; Paulus W; Schneider-Gold C; Chan A; Gold R Muscle Nerve; 2008 Mar; 37(3):406-9. PubMed ID: 17918749 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]